Quarterly report [Sections 13 or 15(d)]

Schedule of Segment Financial Information (Details)

v3.26.1
Schedule of Segment Financial Information (Details) - USD ($)
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Segment Reporting [Line Items]    
Total research and development $ 383,724 $ 1,281,141
Total selling, general and administrative 1,542,658 1,058,662
Interest income 78,676 36,216
Net loss (1,847,706) (2,303,587)
Clinincal [Member]    
Segment Reporting [Line Items]    
Total research and development 726,321
Chemistry Manufacturing and Controls [Member]    
Segment Reporting [Line Items]    
Total research and development 32,502 125,290
Personnel Related [Member]    
Segment Reporting [Line Items]    
Total research and development 351,222 429,530
Total selling, general and administrative 324,529 339,018
Compliance [Member]    
Segment Reporting [Line Items]    
Total selling, general and administrative 1,011,796 719,644
Marketing Expense [Member]    
Segment Reporting [Line Items]    
Total selling, general and administrative $ 206,333